kyprolis
amgen europe b.v. - carfilzomib - szpiczak mnogi - Środki przeciwnowotworowe - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
sarclisa
sanofi winthrop industrie - isatuximab - szpiczak mnogi - Środki przeciwnowotworowe - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
cardilopin 5 mg tabletki
proterapia sp. z o.o. - amlodipinum - tabletki - 5 mg
cardilopin 10 mg tabletki
proterapia sp. z o.o. - amlodipinum - tabletki - 10 mg
cardilopin 2,5 mg tabletki
proterapia sp. z o.o. - amlodipinum - tabletki - 2,5 mg
empliciti
bristol-myers squibb pharma eeig - elotuzumab - szpiczak mnogi - Środki przeciwnowotworowe - empliciti podano w połączeniu z леналидомидом i deksametazon do leczenia szpiczaka mnogiego u dorosłych pacjentów, którzy otrzymali co najmniej jeden kurs terapii (patrz rozdziały 4. 2 i 5.